San Diego startup cAMPfield Therapeutics raised $180 million in a Series A, according to the announcement, positioning the company to develop inflammatory and immunology therapies built on licensed mechanisms. The round signals continued investor appetite for mature platform concepts when partnered licensing reduces technology risk. The funding is being interpreted as part of a broader shift toward backing programs that can demonstrate differentiation in immunology biology, while leveraging external intellectual property licensed from other companies. For founders and investors, the scale of Series A capital suggests expectations for near-term pipeline progression rather than long horizon preclinical work. As the company ramps, investors will likely focus on translational biomarkers and early clinical signals that can validate the inflammatory pathway strategy behind its lead programs.